Vol. 6 No. 1 (2026)
Reimbursement Reviews

Relugolix, Estradiol, and Norethindrone Acetate (Myfembree)

decorative image of the issue cover

Published January 6, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses relugolix-estradiol–norethindrone acetate (Myfembree) 40 mg/1 mg/0.5 mg, oral tablet.
  • Indication: In premenopausal women for the management of heavy menstrual bleeding associated with uterine fibroids and for the management of moderate to severe pain associated with endometriosis.